Upcoming data from United Therapeutics Corporation suggest earlier detection and treatment may improve outcomes in pulmonary hypertension, with findings to be presented at the ISHLT 46th Annual Meeting and Scientific Sessions.
Written By: Chikkula Pavan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
Emerging data presented by United Therapeutics suggest that earlier detection and more proactive treatment could play a critical role in improving outcomes for patients with pulmonary hypertension (PH). Findings from two ongoing studies highlight the potential benefits of identifying the condition sooner in high-risk populations and initiating therapy earlier in the disease course.
Interim results from the PHINDER study indicate that non-invasive measures may help detect PH earlier in patients with interstitial lung disease (ILD), a group in whom diagnosis is often delayed. Earlier identification could enable more timely intervention and potentially slow disease progression.
At the same time, data from the ARTISAN study suggest that early, high-dose treatment with Treprostinil may significantly improve cardiac function in patients with pulmonary arterial hypertension (PAH).
Investigators reported reductions in afterload, improvements in right ventricular performance, and signs of reverse cardiac remodelling, pointing to the potential impact of treating aggressively at an earlier stage.
These findings are expected to be presented at the ISHLT 46th Annual Meeting and Scientific Sessions, taking place April 22–25, 2026, in Toronto reflect a broader shift toward earlier intervention in PH, although full study results are still awaited.
Reference
About the Writer
Chikkula Pavan Kumar, Pharm.D is a Doctor of Pharmacy with a keen interest in clinical pharmacy, pharmacovigilance, and evidence-based practice. In his words, he is passionate about patient safety and translating complex medical information into clear, research-driven communication.